This effect results from two different mechanisms: the anti-CD19 CAR, although it interferes with tumor binding by CAR cells, favors the detachment of anti-CD19 CAR cells from target cells, thus, facilitating improved serial killing; the reduced interaction between CAR cells and tumor targets reduces CAR-induced trogocytosis [27]. The gene discussed is CD19; the disease is neoplasm.